Amgen Inc. (AMGN) earnings on November 3, 2026

After the market closes Q3 2026

More Amgen Inc. earnings

Prior outlook: Optimistic Outcome: Accurate

AMGN rose after earnings, as analysts raised their expected prices for the stock.

AMGN price around the earnings

478.48

Change: +3.7%

2026-11-04, 21:00 UTC

Start of the measured window End of the measured window
448.08 463.52 478.95 494.39 461.26
Price series around the eventClosing price per minute from before the event to the end of the measured window.No trading (market closed)
November 3, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • No trading (market closed)
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Accurate

Thesis published
Results released

Optimistic scenario

The setup points optimistic: AMGN has strong recent trend strength and has beaten earnings expectations in recent quarters. Analysts are more cautious, but the price structure carries more weight in this view.

Context analyzed before publication

Summary
Optimistic scenario
Playbook
AMGN has outperformed the Nasdaq-100 ETF over 30 days and sits near its 52-week high, while analysts' targets remain below the current price.
Trend
Optimistic outlook persists despite score fluctuations

Analysts

Drivers

  • Analysts Negative

    Most analysts rate AMGN Hold across 29 opinions, with a slightly negative tilt, while the scenario points optimistic despite a stated $397 target.

Evidence

Analyst consensus
Hold
Consensus average (1-5)
2.65
Analysts covering the stock
29
Average price target
397.32
Lowest price target
225
Highest price target
500
Upside to price target
-13.8%
Quarterly earnings growth
65.9%
Revenue growth
9.5%
Forward EPS
24.5
Trailing EPS
16.1
Analyst moves in the last 60 days
10
  • Strong buy: 4
  • Buy: 8
  • Hold: 17
  • Sell: 3
  • Strong sell: 2
Strong buy
4
Buy
8
Hold
17
Sell
3
Strong sell
2
  • October 23, 2026 · Oppenheimer: Maintains rating (Outperform → Outperform)
  • October 21, 2026 · Barclays: Maintains rating (Equal-Weight → Equal-Weight)
  • October 13, 2026 · Guggenheim: Maintains rating (Neutral → Neutral)
  • October 12, 2026 · BMO Capital: Maintains rating (Market Perform → Market Perform)
  • October 12, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
  • October 9, 2026 · UBS: Maintains rating (Buy → Buy)
  • October 8, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
  • October 8, 2026 · Cantor Fitzgerald: Maintains rating (Neutral → Neutral)
  • October 7, 2026 · Truist Securities: Maintains rating (Hold → Hold)
  • October 7, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)

News and sentiment

Drivers

  • News & sentiment Neutral

    The headlines focus on broad market themes rather than AMGN specifically, and optimistic social-media discussion has limited supporting evidence.

Evidence

Sentiment
Sentiment
Constructive
Mention volume
High
Normalized volume
99%
Messages
30

Technicals

Drivers

  • Technical Positive

    Over the past 30 days, AMGN gained 15.47% while the Nasdaq-100 ETF fell 9.11%, showing stronger performance by 24.58 percentage points.

Evidence

Price when the context was analyzed
465.45
Average true range (ATR)
2.4%
Distance to 52-week high
-1.1%
14-day change (14d)
+9.5%
30-day change (31d)
+15.5%
30-day relative strength
+24.6%
QQQ change (31d)
-9.1%
Nearest support
465.25
Distance to nearest support
0%
Nearest resistance
468.08
Distance to nearest resistance
0.6%
Volume accumulation ratio (14d / 46d)
0.96
  • Minor: 465.25 (0% away, 0.02 ATR, 4 touches)
  • Mid: 460.92 (1% away, 0.4 ATR, 6 touches)
  • Minor: 457.4 (1.7% away, 0.72 ATR, 2 touches)
  • Mid: 468.08 (0.6% away, 0.24 ATR, 9 touches)
  • Minor: 472.99 (1.6% away, 0.67 ATR, 3 touches)

Trends

Drivers

  • Macro & trends Positive

    A 15.47% gain over 30 days places AMGN near its 52-week high and shows clear trend strength.

Evidence

Average earnings surprise
+11.1%
  • August 4, 2026: actual EPS 6.29 vs estimate 5.62 (surprise +12.0%)
  • April 30, 2026: actual EPS 5.15 vs estimate 4.77 (surprise +8.0%)
  • February 3, 2026: actual EPS 5.29 vs estimate 4.73 (surprise +11.9%)
  • November 4, 2025: actual EPS 5.64 vs estimate 5.01 (surprise +12.5%)

Expected move

Drivers

  • Past earnings Positive

    The last four reported earnings-per-share results exceeded analyst estimates by 8.0% to 12.5%, though market reactions after results have been mixed.

Implied move
+3.1%
Source
Options chain

Reactions over its last 21 earnings

Median move
4.7%
75th percentile move
6.4%
90th percentile move
7.9%
Up / down moves
10 / 11
Average up move
+5.6%
Average down move
-3.5%

Monitoring and close

What Amgen Inc. reported

Status
Finished
Actual EPS6.45
EPS estimate5.79
EPS surprise+11.4%
Revenue$10,365 million
Revenue estimate$10,071 million
Revenue surprise+2.9%

Amgen beat Q3 estimates and raised 2026 guidance, with shares up 5.91%. Adjusted EPS reached $6.45 versus $5.76 expected, while revenue was $10.40 billion.

Sources (39)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating +5.6% pre-market, a move in line with the stock's usual reaction (about 5%). The figures confirm the optimistic scenario. Across our market history, in the 1,193 similar cases the close held that direction 84% of the time.

How the stock reacted

Outcome
Accurate
Consolidated
+3.7%
Max favorable move (MFE)
7.2%
Max adverse move (MAE)
2.9%